Cucurbitacin E Inhibits Cellular Proliferation and Enhances the Chemo-response in Gastric Cancer by Suppressing AKt Activation

Overview

Journal J Cancer

Specialty Oncology

Date 2019 Nov 19

PMID 31737120

Citations 11

Authors

Wenzhang Si

Jia Lyu

Zhengchuang Liu

Chunyang Wang

Jingjing Huang

Liping Jiang

Tonghui Ma

Affiliations

Soon will be listed here.

Abstract

The incidence and mortality rate of gastric cancer has markedly declined over the past few decades, due to the progress and advances in the development of diagnostic and treatment regimens. However, there is still a large portion of patients who are first diagnosed during the advanced stage of gastric cancer when chemotherapy is needed. Unfortunately, resistance to chemotherapeutic agents is the most frequent occurrence during treatment, which indicates a need for the discovery of novel therapeutic anticancer drugs. The tumor-suppression effect of eight different cucurbitacins was evaluated in gastric cancer cell lines, and the Cucurbitacin E (CuE) showing the greatest effect was used in further studies to explore the mechanism and potential synergistic effect of Dox both and . Compared with other cucurbitacins, CuE showed the greatest antiproliferative activity against the gastric cancer cell lines. Further investigations revealed that CuE suppressed the growth of gastric cancer cell lines through the induction of G2/M arrest and subsequent apoptosis by impairing AKt activation and reducing its expression in gastric cancer cells. Furthermore, our results indicate that CuE can significantly enhance the cytotoxicity of doxorubicin (Dox) both and . In summary, we present the first evidence of the efficacy of CuE for the inhibition of gastric cancer growth and the synergistic antitumorigenic effect of CuE and Dox, both and .

Citing Articles

Efficacy of natural NF-κB inhibitors in the treatment of fibrosarcoma: an in vitro model study.

Radzka J, Gizak A, Drag-Zalesinska M, Haczkiewicz-Lesniak K, Kulus M, Szewczyk A Front Cell Dev Biol. 2025; 12:1476007.

PMID: 39763587 PMC: 11701009. DOI: 10.3389/fcell.2024.1476007.

Cucurbitacin E elicits apoptosis in laryngeal squamous cell carcinoma by enhancing reactive oxygen species-regulated mitochondrial dysfunction and endoplasmic reticulum stress.

Zheng X, Tang P, Li H, Ye T, Zhu X, He W Am J Cancer Res. 2024; 14(8):3905-3921.

PMID: 39267666 PMC: 11387858. DOI: 10.62347/HPQQ9412.

Plant-Derived Terpenoids: A Plethora of Bioactive Compounds with Several Health Functions and Industrial Applications-A Comprehensive Overview.

Camara J, Perestrelo R, Ferreira R, Berenguer C, Pereira J, Castilho P Molecules. 2024; 29(16).

PMID: 39202940 PMC: 11357518. DOI: 10.3390/molecules29163861.

Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer.

Li S, Wang S, Zhang A, Luo L, Song J, Wei G Int J Oncol. 2024; 64(4).

PMID: 38391053 PMC: 10901535. DOI: 10.3892/ijo.2024.5625.

Recent Advances in the Application of Cucurbitacins as Anticancer Agents.

Zieniuk B, Pawelkowicz M Metabolites. 2023; 13(10).

PMID: 37887406 PMC: 10608718. DOI: 10.3390/metabo13101081.

References

Ornelas I, Silva T, Fragel-Madeira L, Ventura A . Inhibition of PI3K/Akt pathway impairs G2/M transition of cell cycle in late developing progenitors of the avian embryo retina. PLoS One. 2013; 8(1):e53517. PMC: 3534656. DOI: 10.1371/journal.pone.0053517. View

Escandell J, Recio M, Manez S, Giner R, Cerda-Nicolas M, Gil-Benso R . Dihydrocucurbitacin B inhibits delayed type hypersensitivity reactions by suppressing lymphocyte proliferation. J Pharmacol Exp Ther. 2007; 322(3):1261-8. DOI: 10.1124/jpet.107.122671. View

Lordick F, Lorenzen S, Yamada Y, Ilson D . Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric Cancer. 2013; 17(2):213-25. DOI: 10.1007/s10120-013-0297-z. View

Chen J, Chiu M, Nie R, Cordell G, Qiu S . Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep. 2005; 22(3):386-99. DOI: 10.1039/b418841c. View

Zheng L, Wu C, Xi P, Zhu M, Zhang L, Chen S . The survival and the long-term trends of patients with gastric cancer in Shanghai, China. BMC Cancer. 2014; 14:300. PMC: 4243141. DOI: 10.1186/1471-2407-14-300. View

Zhao L, Miao H, Li W, Sun Y, Huang S, Li Z . LW-213 induces G2/M cell cycle arrest through AKT/GSK3β/β-catenin signaling pathway in human breast cancer cells. Mol Carcinog. 2015; 55(5):778-92. DOI: 10.1002/mc.22321. View

Jayaprakasam B, Seeram N, Nair M . Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett. 2002; 189(1):11-6. DOI: 10.1016/s0304-3835(02)00497-4. View

West K, Castillo S, Dennis P . Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2003; 5(6):234-48. DOI: 10.1016/s1368-7646(02)00120-6. View

Kim A, Khursigara G, Sun X, Franke T, Chao M . Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001; 21(3):893-901. PMC: 86680. DOI: 10.1128/MCB.21.3.893-901.2001. View

10.

Majeed W, Iftikhar A, Khaliq T, Aslam B, Muzaffar H, Atta K . Gastric Carcinoma: Recent Trends in Diagnostic Biomarkers and Molecular Targeted Therapies. Asian Pac J Cancer Prev. 2016; 17(7):3053-60. View

11.

de Frias M, Iglesias-Serret D, Cosialls A, Coll-Mulet L, Santidrian A, Gonzalez-Girones D . Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2009; 94(12):1698-707. PMC: 2791940. DOI: 10.3324/haematol.2008.004028. View

12.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

13.

Wang L, Li C, Lin Q, Zhang X, Pan H, Xu L . Cucurbitacin E suppresses cytokine expression in human Jurkat T cells through down-regulating the NF-κB signaling. Acta Biochim Biophys Sin (Shanghai). 2015; 47(6):459-65. DOI: 10.1093/abbs/gmv030. View

14.

Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R . Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. Br J Cancer. 2014; 111(8):1552-61. PMC: 4200093. DOI: 10.1038/bjc.2014.453. View

15.

Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb H, Bergman M . Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol. 2006; 73(1):56-67. DOI: 10.1016/j.bcp.2006.09.012. View

16.

Wagner A, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18):2903-9. DOI: 10.1200/JCO.2005.05.0245. View

17.

Shang Y, Guo X, Li W, Rao W, Chen M, Mu L . Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN. Eur Rev Med Pharmacol Sci. 2014; 18(21):3297-303. View

18.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

19.

Lee S, Park J, Park E, Chung C, Kang S, Bang O . Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol. 2005; 205(2):270-7. DOI: 10.1002/jcp.20395. View

20.

Song Y, Ding N, Kanazawa T, Yamashita U, Yoshida Y . Cucurbitacin D is a new inflammasome activator in macrophages. Int Immunopharmacol. 2013; 17(4):1044-50. DOI: 10.1016/j.intimp.2013.10.003. View